Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

BioPulse faces US and Mexican malpractice probes

Article Abstract:

On February 2 2001, The U.S. Federal Trade Commission opened an investigation into BioPulse International's claim on its website that it can successully treat cancer patients with up to 95 percent effectiveness, using the company's unproven methods at its Tijuana clinic. On February 15, the Mexican government closed part of the clinic.

Author: Niiler, Eric
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2001
Administration of General Economic Programs, Advertising, New Electronic Marketing, Mexico, Admin. of general economic programs, Federal Trade Commission, Biopulse International Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Company, academics argue over data

Article Abstract:

Immune Response Corp. filed suit against the University of California San Francisco, and Harvard University for publishing phase III drug trial information, which suggests that the company's HIV drug Remune is no more effective than a placebo in fighting HIV infection.

Author: Niiler, Eric
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
Marketing procedures, Company Planning/Goals, California, Massachusetts, General Medical and Surgical Hospitals, General medical & surgical hospitals, Antiinfective Preparations NEC, University Medical Centers, Anti-infective agents, University hospitals, Remune (Medication), Immune Response Corp., IMNR

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Analysts: Isis-Lilly deal validates antisense

Article Abstract:

Eli Lilly and Isis Pharmaceuticals strike a deal to facilitate development of "antisense" technology, which interferes with production of disease-causing proteins in RNA. Eli Lilly would also receive rights to lung cancer drug, ISIS 3521, as part of the agreement.

Author: Niiler, Eric
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2001
Biological Product (except Diagnostic) Manufacturing, Strategic alliances, Drugs, Oligonucleotides, Eli Lilly and Co., Isis Pharmaceuticals Inc., LLY, Nucleotides, ISIP

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Antineoplastic agents
Similar abstracts:
  • Abstracts: Electronic commerce: its potential and its methods. Web-based business valuation. Web-based business models
  • Abstracts: The real-time costs of dealing online. Casting the net wider. Choosing an online broker
  • Abstracts: Three weddings and a funeral. There are still good bargains to be sniffed out. Secure profits
  • Abstracts: Single market, multiple problems. The integrated path to success. Can you risk it?
  • Abstracts: Social and environmental accounting: trends and directions for the future. Social and environmental accounting and student choice: an exploratory research note
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.